Aims Statin intolerance (SI) represents a significant public health problem for which precise
estimates of prevalence are needed. Statin intolerance remains an important clinical …

There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein
cholesterol) to reduce cardiovascular morbidity and mortality. Statins are a class of drugs …

Background Statin therapy is effective for the prevention of atherosclerotic cardiovascular
disease and is widely prescribed, but there are persisting concerns that statin therapy might …

One in 4 Americans> 40 years of age takes a statin to reduce the risk of myocardial
infarction, ischemic stroke, and other complications of atherosclerotic disease. The most …

Background: Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for
atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with …

Importance The comparative clinical benefit of nonstatin therapies that reduce low-density
lipoprotein cholesterol (LDL-C) remains uncertain. Objective To evaluate the association …

Importance Effects on specific fatal and nonfatal end points appear to vary for low-density
lipoprotein cholesterol (LDL-C)–lowering drug trials. Objective To evaluate whether baseline …

The 2013 ACC/AHA guidelines on blood cholesterol management were a major shift in the
delineation of the main patient groups that could benefit from statin therapy and emphasized …

Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are well
tolerated, but associated with various statin-associated symptoms (SAS), including statin …

Background Patients with evidence of vascular disease are at increased risk for subsequent
vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) …